HFpEF Gets a More Personal Plan: What New Diabetes and Liver Studies Add (2026)

The week's formal practice update is a new American College of Cardiology pathway for heart failure with preserved ejection fraction (HFpEF), a type of heart failure in which the heart's squeezing percentage may look normal even though symptoms and pressure problems are real. Three studies published July 21 add patient questions about oral semaglutide, MASLD/MASH, and metformin during high-intensity exercise. The pathway can inform care now; the studies are evidence to discuss, not instructions to change medicines.

If this sounds like you	What changed	What to do with it
You have HFpEF, breathlessness, or swelling	The ACC published its 2026 Expert Consensus Decision Pathway online July 23. It treats HFpEF as a multisystem syndrome and gives practical guidance on SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, incretin-based therapies, diuretics, exercise, calorie restriction, and related conditions such as diabetes, obesity, high blood pressure, kidney disease, and atrial fibrillation. 1	Ask whether HFpEF has been confirmed, which conditions may be worsening it, and which treatment fits your blood pressure, kidney function, diabetes care, and symptoms.
You take or are considering oral semaglutide for type 2 diabetes with heart or kidney disease	A post hoc analysis of the SOUL trial followed 9,650 adults for a median 47.5 months. The cardiovascular benefit of oral semaglutide appeared more pronounced in people with higher starting A1c and greater A1c reductions, but it was consistent across starting BMI and BMI changes. 2	Do not change a dose based on weight alone. Ask what the medicine is meant to improve, what A1c goal applies to you, and how your heart, kidney, glucose, and side-effect follow-up will be handled.
You have MASLD or MASH and see headlines about new liver drugs	In a 67-person phase 2 trial, 25 of 33 people receiving the investigational drug DD01 had at least a 30% relative reduction in MRI-measured liver fat at week 12, compared with 4 of 34 receiving placebo. Nausea, diarrhea, and vomiting were more common with DD01. 3	Treat this as early research, not a prescription or proof of less scarring. Ask how your fibrosis risk is being assessed and which proven steps fit your current liver findings.
You take metformin and are starting high-intensity exercise	In a 16-week double-blind trial of adults with metabolic-syndrome risk, high-intensity exercise plus metformin was followed by glucose levels about 18-21 mg/dL higher at 1 and 2 hours after a 75-gram glucose drink than the same exercise plus placebo. 4	Do not stop metformin on your own. Ask whether your training intensity, medication plan, and glucose checks should be reviewed together.

1. HFpEF gets a more personal plan

The ACC pathway updates a 2023 consensus document. Its practical message is that HFpEF is not one uniform condition. A person with obesity and sleep-related breathing problems may need a different plan from someone whose main issues are atrial fibrillation, kidney disease, high blood pressure, or diabetes. The document also stresses that symptoms such as breathlessness and swelling need a careful diagnosis because several conditions can look like HFpEF.

For a visit, bring a short record of when symptoms appear, your home blood-pressure readings if you have them, your current medication list, and any recent changes in exercise tolerance. The useful question is not simply, "Which new heart-failure drug should I take?" It is: "Which part of my HFpEF picture is driving my symptoms, and which treatment has evidence for someone with my other conditions?"

The pathway includes medication and non-medication care. That means a treatment conversation can include exercise, food intake, blood pressure, diabetes, kidney health, rhythm problems, and weight, rather than treating each item as a separate appointment.

2. Oral semaglutide's heart benefit was not explained by weight loss alone

The SOUL analysis was post hoc, meaning the investigators looked back at a completed randomized trial to ask a new question. It was not a trial that assigned people to different A1c targets, and it does not prove that everyone should push A1c lower.

The result is more specific: among adults with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease, the observed cardiovascular benefit of oral semaglutide was greater in groups with higher starting A1c and larger A1c reductions. The pattern was similar across BMI categories. That gives clinicians more context when discussing why the drug is being used, but it does not turn BMI or A1c into a personal prescribing rule.

Ask: "Is my oral semaglutide plan aimed mainly at glucose control, heart-risk reduction, kidney protection, or more than one of these?" The answer should also include how often your A1c, kidney tests, weight, and side effects will be reviewed.

3. DD01 reduced liver fat quickly, but the study did not answer the hardest liver questions

DD01 is an investigational, once-weekly dual GLP-1 and glucagon receptor agonist. In the 12-week analysis, 76% of people assigned to DD01 reached the study's liver-fat reduction threshold, compared with 12% assigned to placebo. The trial's primary endpoint was MRI-measured liver fat, not a demonstrated reduction in advanced fibrosis, liver cancer, transplant, or death.

The study was small, and the full 48-week trial is still ongoing. Side effects were also part of the result: nausea occurred in 55% of the DD01 group versus 18% of the placebo group, and 12% of the DD01 group stopped treatment because of treatment-emergent adverse events versus 3% of the placebo group. The work was funded by D&D Pharmatech and Neuraly, and several authors reported company relationships.

For someone living with MASLD or MASH, the actionable question is still about risk assessment and an individualized plan. Ask what your fibrosis tests show, whether the result needs repeating, and which lifestyle or approved treatment steps are appropriate. A reduction in liver fat on an early trial endpoint is encouraging research, not a reason to seek an unapproved drug.

4. The metformin and exercise result needs context

This study involved 91 adults with metabolic-syndrome risk, not every person who takes metformin. Participants were assigned to lower- or higher-intensity exercise with either metformin or placebo for 16 weeks. The signal appeared in the higher-intensity metformin group: glucose after the standardized drink was higher than in the matching high-intensity placebo group.

That finding does not show that exercise is harmful, or that metformin should generally be stopped. It does raise a practical question about whether medication, exercise intensity, and glucose monitoring should be planned as one package for some patients. A clinician may also decide that the result does not apply to a particular person because the study population, exercise program, or treatment goal is different.

If you are starting a demanding exercise program, ask when to check glucose, what symptoms should prompt a pause, and whether your medication schedule needs review. Keep the medication decision with the clinician who knows your health history.

Four questions to take to your next appointment

Could my breathlessness or swelling be HFpEF, another heart problem, or a condition outside the heart, and what evidence supports that assessment?
If I use oral semaglutide, what is the main goal of my treatment and how will we track benefit and side effects?
For my MASLD or MASH, what is my fibrosis risk, and how will we know if the plan is working?
If I combine metformin with higher-intensity exercise, what glucose checks and warning signs should guide my plan?

These updates are useful for preparing a better conversation, not for changing a prescription without medical advice.

This article is for appointment preparation and caregiver discussion. It does not replace individualized medical advice.

HFpEF Gets a More Personal Plan: What New Diabetes and Liver Studies Add